Nm23 Activator Small Molecule for Cancer Metastasis Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer metastasis suppressing drugs, particularly those using cell-permeable Nm23-H1, face challenges with in vivo stability and short treatment duration, limiting their effectiveness and making them high-cost options.
Innovation Solution
A pharmaceutical composition containing a novel Nm23 activator, represented by Formula 1 or its stereoisomers/pharmaceutically acceptable salts, which modulates Nm23 activity to suppress cancer metastasis by enhancing NDPK activity, thereby inhibiting cancer cell invasion and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cell-permeable Nm23-H1 is used to suppress cancer metastasis, then metastasis suppressing activity is achieved, but in vivo stability is poor and treatment duration is short
Solution Approach 1:
The patent uses a small molecule activator as an intermediary substance that indirectly activates Nm23-H1 rather than administering Nm23-H1 directly. This small molecule penetrates cell membranes easily and triggers endogenous Nm23-H1 activation, solving the stability problem while maintaining metastasis suppressing activity. The activator serves as a mediator between the external treatment and the internal Nm23-H1 pathway.
Solution Approach 2:
The patent enables the body's own Nm23-H1 protein to perform the metastasis suppressing function by activating it with a small molecule. Instead of relying on externally administered protein drugs that degrade quickly, the treatment stimulates the body's endogenous Nm23-H1 to carry out the therapeutic effect continuously, improving both stability and duration of action.
2Reliability
If cell-permeable Nm23-H1 is used for cancer metastasis suppression, then therapeutic effect is achieved, but treatment cost is high
Solution Approach 1:
The patent replaces expensive protein drugs with small molecule activators that are cheaper to manufacture. Although the small molecules may have shorter individual half-lives, their ability to repeatedly activate endogenous Nm23-H1 creates sustained therapeutic effects at lower cost. The small molecules serve as reusable triggers rather than single-use protein therapeutics.
Solution Approach 2:
Instead of administering the actual Nm23-H1 protein (the expensive original), the patent uses small molecule copies or analogs that can trigger the same biological response. These small molecule surrogates are much cheaper to produce while achieving comparable therapeutic outcomes through indirect activation of the target pathway.
3Reliability
If MPA is used to increase Nm23-H1 expression, then metastasis suppression is achieved, but unexpected intracellular responses occur
Solution Approach 1:
The patent uses small molecule activators that specifically target and activate only Nm23-H1 without triggering broad intracellular responses. Unlike MPA which causes systemic effects, the small molecule activators act locally and selectively on the Nm23-H1 pathway, achieving metastasis suppression with minimal off-target effects and unexpected intracellular responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively suppresses cancer metastasis by increasing Nm23-H1 and Nm23-H2 activity, demonstrating significant metastasis inhibition in breast cancer models, with potential applications in various cancer types.
Implementation Method 1
Nm23 protein consisting of 150 to 180 amino acids comprises a leucine zipper motif and has a dinucleotide phosphate kinase (NDPK) activity
Data Source
AI summary
The present disclosure relates to a pharmaceutical composition for suppressing cancer metastasis containing, as an active ingredient, an activator compound of the cancer metastasis inhibitor Nm23, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound according to the present disclosure may suppress the metastasis of cancer cells by promoting the activity of Nm23 associated with cancer metastasis, and thus may be useful as a pharmaceutical composition for suppressing cancer metastasis.